GLP-1 Semaglutide & Tirzepatide Calculator
GLP-1 Reconstitution & Dose Calculator
Semaglutide & Tirzepatide — reconstitution, IU draw, titration schedule, vial duration.
Inputs
Standard titration schedule
| Phase | Weeks | Weekly dose | IU on this syringe |
|---|
Frequently Asked Questions
Q1What are GLP-1 receptor agonists and how do they work?
GLP-1 (glucagon-like peptide-1) receptor agonists mimic the body's incretin hormone GLP-1. They stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central nervous system signaling. These mechanisms are studied for their combined effects on blood glucose regulation and body composition.
Q2What is the difference between semaglutide and tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist with a ~7-day half-life, allowing once-weekly administration. Tirzepatide is a dual GIP/GLP-1 receptor agonist—its additional GIP activity produces a distinct and often more pronounced metabolic response in research settings compared to GLP-1 agonism alone.
Q3How do I calculate the injection volume for a reconstituted GLP-1 peptide?
Divide your target dose (mcg) by the concentration (mcg/mL) to get the volume in mL. For example: a 250 mcg dose from a vial reconstituted to 1,000 mcg/mL requires 0.25 mL = 25 units on a 100-unit insulin syringe. The GLP-1 Calculator above performs this conversion for your specific vial and dose.
Q4Why is gradual dose escalation used in GLP-1 research protocols?
Dose escalation minimizes GI side effects (nausea, vomiting) that commonly occur at full therapeutic doses. Starting at a low dose (e.g. 0.25 mg semaglutide weekly) and increasing every 4 weeks allows the body to adapt. Most research protocols follow a structured titration schedule over 16–20 weeks.